Startup Pinnacle Medicines is developing peptide drugs with the same efficacy as biologic medicines and the dosing convenience of oral small molecules. The lead program of OrbiMed-incubated Pinnacle is on track to enter the clinic in asthma and chronic obstructive pulmonary disease.
The post Pinnacle Medicines Adds $89M for Oral Peptides With Properties of Injectable Biologics appeared first on MedCity News.
StockWatch: Price War Dampens Lilly Surge After Oral GLP-1 Wins FDA Nod
Eli Lilly (NYSE: LLY) won the approval it sought when the FDA authorized the company’s oral obesity drug Foundayo (orforglipron), but the pharma giant’s post-approval
